the cube journal

A new era has begun

A NEW ERA HAS BEGUN

We have crossed a new frontier by setting up a strategy that aims at investing in the biotech and the healthcare sectors. More than ever, we believe that the value of change lies in an interdisciplinary approach to life improvement that puts human well-being at the center.

In the last few years we have, together with our partners, many successful investments in this field.

-

DIRECT INVESTMENTS:

23andMe - 23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits, with the aim to help people in understanding what their genes mean by indexing them and highlighting significant findings.

Alpha Health - Alpha Health provides hospitals with Unified Automation services, which is a flexible AI-based solution that automates complex operational tasks such as those related to revenue cycle management.

Andrew Alliance - Andrew Alliance is the Swiss pioneer in robotics for the Life Sciences sector, dedicated to advanced science by working with scientists to create a new class of easy to use robots and connected devices that take repeatability, performance and efficiency of the laboratory to the level required by 21st century biology.

Calm - Calm is a digital health platform that provides guided meditation sessions and mindfulness training to reduce anxiety and sleep better, by  developing a range of digital and physical products that enhance mental fitness and alleviate some of the most important mental health issues of the modern age.

CandidCo - The company helps people get the smile they've always wanted at a price they can afford. Candid Co's network of professional orthodontists oversees the entire treatment process from planning to evaluation to manufacturing.

Capsule - Capsule is a healthcare technology business rebuilding the pharmacy from the inside out with an emotionally resonant experience, and technology that enables customized outcomes for doctors, hospitals, insurers, and manufacturers.

Headspace - Headspace is a digital health platform that provides guided meditation sessions and mindfulness training. With hundreds of hours of content, it is acknowledged as one of the most comprehensive secular programs for meditation and mindfulness.

HeartFlow - HeartFlow is a medical technology company that provides new methods of diagnosis and treatment of cardiovascular disease, evolutionizing precision heart care. 

Redesign Health - Redesign Health is a healthcare innovation platform that focuses on healthcare companies, its mission-driven is to transform the healthcare system - elevating patient experience, increasing transparency, and democratizing access to high-quality care.

Tensive - Tensive is a biomedical startup established in 2012 to develop innovative prostheses aiming to offer a natural breast reconstruction or augmentation. 

-

INVESTMENTS IN FUNDS:

Apollo Health Ventures - Early Stage Investment Firm accelerating breakthrough scientific discoveries and building life science companies around new therapeutic technologies to prevent or reverse age-related diseases and extend healthy human lifespan.

KdT Ventures - New age seed stage venture firm, with a focus on the intersection of technology and science. With the goal to help entrepreneurs turn their own ideas and visions into successful,impactful companies.

Oxford Sciences Innovation - The world’s largest university-partnered venture firm. Working with the University of Oxford to build companies that create science-based businesses capable of tackling the planet’s toughest problems.

Red Tree Venture Capital - The firm invests into make minority stakes in seed-stage, early-stage, and later-stage companies across the life sciences sector, with a focus on Drugs/Med Devices/Diagnostics to address diseases in Neuro, Oncology & Immunology field.

-

We have also invested in Omega's new fund!

Omega Funds is a pharma and biotech investment firm founded in 2004 and based in Boston (Massachusetts, US): Omega aims to develop and invest in life science companies targeting the world’s most urgent medical needs across a multitude of therapeutic areas including oncology, immunology, precision medicine, rare diseases and occasionally devices or platform technologies.

The last letter of the Greek alphabet “Ω” encompasses Omega’s brand, and its investment strategy: Omega specializes in identifying and powering companies through value inflection points across the full arc of innovation, from company formation through clinical milestones and commercial adoption.

Agnostic in terms of stage, Omega often leads Series A or B financings and typically receives board seats, however early/seed rounds as well as later stages are also targeted: it has invested so far in 100+ companies, of which 35 have been acquired and 39 have completed public listings. Since its inception, the firm has raised more than $1.7bn and helped bring 46 products to market, many changing the course of treatment for patients with devastating diseases such as acute lymphoblastic leukemia, melanoma, and Huntington’s disease.

 

BioCube Night - We hosted the special guest Riccardo Sabatini

September 2nd, 2021

"We are entering in the era of programmable biology: modern tools of molecular modeling and detection allow us to gain precision and visibility on biological mechanisms that were unthinkable a few years ago. And as in software, we're now getting better and better at drive human biology to intended outcomes in a rational way. This is what programming really is, and this is how biotech will look in the next decades".

Riccardo Sabatini

 

Previous

BTV, building a better future